C
Cabaletta Bio D
D
CABA
1.78500
USD
0.05
(2.59%)
Market Closed
Volume
30,390
EPS
-3
Div Yield
-
P/E
-1
Market Cap
160,548,435
News
Title: Cabaletta Bio
Sector: Healthcare
Industry: Biotechnology
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients withB cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies,or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.